Pharmacological treatment of insomnia;Farmakologiczne leczenie bezsenności

Psychiatria Polska

Volumn 40, Issue 3, 2006, Pages 563-577

  Wichniak, Adam ^a,b   Murawiec, Sławomir ^a   Jernajczyk, Wojciech ^b  

^a Instytut Psychiatrii i Neurologii III Klinika Psychiatryczna Warszawa   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Hypnotic drugs; Insomnia; Treatment

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ESTAZOLAM; FLUNITRAZEPAM; HYPNOTIC AGENT; LORAZEPAM; LORMETAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; NITRAZEPAM; TEMAZEPAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADDICTION; INSOMNIA; MEDICAL RESEARCH; MENTAL DISEASE; PREVALENCE; REVIEW;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; DRUGS, NON-PRESCRIPTION; HUMANS; HYPNOTICS AND SEDATIVES; NONPRESCRIPTION DRUGS; PATIENT EDUCATION; PATIENT EDUCATION AS TOPIC; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33747384274     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch. Gen. Psychiatry 1985; 42: 225-232.
2. Benca RM, Ancoli-Israel S, Moldofsky H. Special considerations in insomnia diagnosis and management: depressed, elderly, and chronic pain populations. J. Clin. Psychiatry 2004; 65, supl. 8: 26-35.
3. Jindal RD, Buysse DJ, Thase ME. Maintenance treatment of insomnia: what can we learn from the depression literature? Am. J. Psychiatry 2004; 161: 19-24.
4. Sateia MJ, Nowell PD. Insomnia. Lancet 2004; 364: 1959-1973.
5. International classification of sleep disorders: diagnostic and coding manual, 2nd ed. Westchester, III: American Academy of Sleep Medicine; 2005.
6. Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 1999; 22: 1134-1156.
7. Szelenberger W. Standardy leczenia bezsenności Polskiego Towarzystwa Badań nad Snem. Sen 2003; 3: 117-126.
8. Walsh JK. Clinical and socioeconomic correlates of insomnia. J. Clin. Psychiatry 2004; 65 supl. 8: 13-19.
9. Jarema M. Leki przeciwlȩkowe. W: Bilikiewicz A, Pużynski S, Rybakowski J, Wciórka J, red. Psychiatria (tom III). Wrocław: Urban & Partner; 2002, 137-151.
10. Szelenberger W, Skalski M. Zaburzenia snu. W: Bilikiewicz A, Pużyński S, Rybakowski J, Wciórka J, red. Psychiatria (tom II). Wrocław: Urban & Partner; 2002, s. 538-554.
11. Rzewuska M. Leczenie bezsenności. W: Rzewuska M, red. Leczenie zaburzeń psychicznych. Warszawa: Wydawnictwo Lekarskie PZWL; 2003, 339-362.
12. Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. A review. Psychopharmacol. 1996; 126: 1-16.
13. Mendelson WB. Hypnotic medications: mechanisms of action and pharmacologic effects. W: Kryger MH, Roth T, Dement WC, red. Principles and practice of sleep medicine. Philadelphia: Elsevier Saunders; 2005, 444-451.
14. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum. Psychopharmacol. 2004; 19: 305-322.
15. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin. Pharmacokinet. 2004; 43: 227-238.
16. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addict. 2003; 98: 1371-1378.
17. Hajak G, Cluydts R, Allain H, Estivill E, Parrino L, Terzano MG, Walsh JK. The challenge of chronic insomnia: is non-nightly hypnotic treatment a feasible alternative ? Eur. Psychiatry 2003; 18: 201-208.
18. Walsh JK, Roehrs T. Pharmacologic treatment of primary insomnia. W: Kryger MH, Roth T, Dement W, red. Principles and practice of sleep medicine. Philadelphia: Elsevier Inc.; 2005, 749-760.
19. Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol. Metab Clin. North Am. 2002; 31: 15-36.
20. Nelson JC. Tricyclic and tetracyclic drugs. W: Schatzberg A, Nemeroff C, red. The American psychiatric publishing textbook of psychopharmacology. Washington DC: American Psychiatric Publishing; 2004, 207-230.
21. Pużyński S. Leki przeciwdepresyjne. W: Bilikiewicz A, Pużyński S, Rybakowski J, Wciórka J, red. Psychiatria (tom III). Wrocław: Urban & Partner; 2003, 59-103.
22. Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J. Clin. Psychiatry 1990; 51 (supl.): 18-22.
23. Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiol. 2002; 46: 197-201.
24. Jernajczyk W, Trojecka A, Wierzbicka A, Wichniak A. Citalopram w leczeniu bezsenności pierwotnej. Psychiatr. Pol. 2004; XXXVIII: 104.
25. Schweitzer PK. Drugs that disturb sleep and wakefulness. W: Kryger MH, Roth T, Dement W, red. Principles and practice of sleep medicine. Philadelphia: Elsevier Inc.; 2005, 499-518.
26. Rzewuska M. Leki przeciwpsychotyczne. W: Bilikiewicz A, Pużyński S, Rybakowski J, Wciórka J, red. Psychiatria (tom III). Wrocław: Urban & Partner; 2003, 1-59.
27. Lindberg N, Virkkunen M, Tani P, Appelberg B, Virkkala J, Rimon R, Porkka-Heiskanen T. Effect of a single-dose of olanzapine on sleep in healthy females and males. Int. Clin. Psychopharmacol. 2002; 17: 177-184.
28. Landowski J. Leki przeciwpsychotyczne II generacji, takie same, ale inne. Wiad. Psychiatr. 2004; 7: 107-112.
29. Roth T, Roehrs T, Koshorek G, Sicklesteel J, Zorick F. Sedative effects of antihistamines. J. Allergy Clin. Immunol. 1987; 80: 94-98.
30. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J. Allergy Clin. Immunol. 1994; 94: 716-724.
31. Houghton PJ. The scientific basis for the reputed activity of valerian. J. Pharm. Pharmacol. 1999; 51: 505-512.
32. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000; 33: 47-53.
33. James SP, Sack DA, Rosenthal NE, Mendelson WB. Melatonin administration in insomnia. Neuropsychopharmacol. 1990; 3: 19-23.
34. Ellis CM, Lemmens G, Parkes JD. Melatonin and insomnia. J. Sleep Res. 1996; 5: 61-65.
35. Hajak G, Ruther E: Insomnie-Schlaflosigkeit. Ursachen, Diagnostik und Therapie. Berlin, Heidelberg, Springer, 1995.